Skip to main content

Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway.

Author(s): Bugaj, Lukasz J; Sabnis, Amit J; Mitchell, Amir; Garbarino, JE; Toettcher, Jared E; et al

Download
To refer to this page use: http://arks.princeton.edu/ark:/88435/pr1jw86m9f
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBugaj, Lukasz J-
dc.contributor.authorSabnis, Amit J-
dc.contributor.authorMitchell, Amir-
dc.contributor.authorGarbarino, JE-
dc.contributor.authorToettcher, Jared E-
dc.contributor.authorBivona, TG-
dc.contributor.authorLim, Wendell A-
dc.date.accessioned2023-12-11T18:45:51Z-
dc.date.available2023-12-11T18:45:51Z-
dc.date.issued2018-08-31en_US
dc.identifier.citationBugaj, LJ, Sabnis, AJ, Mitchell, A, Garbarino, JE, Toettcher, JE, Bivona, TG, Lim, WA. (2018). Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway.. Science (New York, N.Y.), 361 (6405), 10.1126/science.aao3048en_US
dc.identifier.issn0036-8075-
dc.identifier.urihttp://arks.princeton.edu/ark:/88435/pr1jw86m9f-
dc.description.abstractThe Ras-Erk (extracellular signal-regulated kinase) pathway encodes information in its dynamics; the duration and frequency of Erk activity can specify distinct cell fates. To enable dynamic encoding, temporal information must be accurately transmitted from the plasma membrane to the nucleus. We used optogenetic profiling to show that both oncogenic B-Raf mutations and B-Raf inhibitors can cause corruption of this transmission, so that short pulses of input Ras activity are distorted into abnormally long Erk outputs. These changes can reshape downstream transcription and cell fates, resulting in improper decisions to proliferate. These findings illustrate how altered dynamic signal transmission properties, and not just constitutively increased signaling, can contribute to cell proliferation and perhaps cancer, and how optogenetic profiling can dissect mechanisms of signaling dysfunction in disease.en_US
dc.format.extenteaao3048 - eaao3048en_US
dc.languageengen_US
dc.language.isoen_USen_US
dc.relation.ispartofScienceen_US
dc.rightsAuthor's manuscripten_US
dc.titleCancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway.en_US
dc.typeJournal Articleen_US
dc.identifier.doidoi:10.1126/science.aao3048-
dc.identifier.eissn1095-9203-
pu.type.symplectichttp://www.symplectic.co.uk/publications/atom-terms/1.0/journal-articleen_US

Files in This Item:
File Description SizeFormat 
Cancer_mutations_dynamic_Ras_Erk_pathway.pdf1.37 MBAdobe PDFView/Download


Items in OAR@Princeton are protected by copyright, with all rights reserved, unless otherwise indicated.